Corticotropin-releasing hormone modulators and depression

Current Opinion in Investigational Drugs

Volumn 4, Issue 1, 2003, Pages 46-50

  Holsboer, Florian ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Corticotropin releasing hormone; Depression

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; ANTALARMIN; ANTIDEPRESSANT AGENT; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1 ANTAGONIST; HYDROCORTISONE; NBI 30545; SAUVAGINE; UNCLASSIFIED DRUG; UROCORTIN; UROCORTIN 2; UROCORTIN III; UROTENSIN I;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; CORTICOTROPIN BLOOD LEVEL; DEPRESSION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENDOCRINE DISEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MAJOR DEPRESSION; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY;

ANIMALS; CLINICAL TRIALS; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; DRUG DESIGN; HUMANS; PYRIMIDINES; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 0037284475     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology (2000) 23(5):477-501.
2. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science (1981) 213(4514):1394-1397.
3. Holsboer F: Prediction of clinical course by dexamethasone suppression test (DST) response in depressed patients - Physiological and clinical construct validity of the DST. Pharmacopsychiatria (1983) 16(6):186-191.
4. Holsboer F, Von Bardeleben U, Gerken A, Stalla GK, Müller OA: Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med (1984) 311(17):1127.
5. Gold PW, Chrousos G, Kellner C, Post R, Roy A, Augerionos P, Schulte H, Oldfield E, Loriaux DI: Psychiatric implications of basic and clinical studies with corticotropin-releasing factor. Am J Psychiatry (1984) 141(5):619-627.
6. Nemeroff CB, Wilderlow E, Bissette G, Walleus H, Karlsson L, Eklund K, Dilts CD, Lossen PT, Vale W: Elevated concentration of CSF corticotropin-releasing factor-like immunity reactivity in depressed patients. Science (1984) 226(4680):1342-1344.
7. Nemeroff CB, Owens MJ, Bissette G, Andorn AC, Stanley M: Reduced corticotropin-releasing factor receptor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry (1988) 45(6):577-579.
8. Keck ME, Holsboer F: Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides (2001) 22(2):835-844.
9. Spengler D, Rupprecht R, Van LP, Holsboer F: Identification and characterisation of a 3′,5′-cyclic adenosine monophosphate-responsive element in the human corticotropin-releasing hormone gene promoter. Mol Endocrinol (1992) 6(11):1931-1941.
10. Sulser F, Vetulani J, Mobley PL: Mode of action of antidepressant drugs. Biochem Pharmacol (1978) 27(3):257-271.
11. Stout SC, Owens MJ, Nemeroff CB: Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther (2002) 300(3):1085-1092.
12. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA (1995) 92(3):836-840.
13. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE: Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA (2001) 98(5):2843-2848.
14. Hsu SY, Hsueh AJW: Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nat Med (2001) 7(5):605-611.
15. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept (1995) 59(2):229-239.
16. 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res (1999) 33(2):153-163.
17. 2, receptors mediate anxiogenic-like behavior. Regul Pept (1997) 71(1):15-21.
18. Skutella T, Probst JC, Renner R, Holsboer F, Behl C: Corticotropin-releasing hormone receptor (type 1) antisense targeting reduces anxiety. Neuroscience (1998) 85(3):795-805.
19. 1, stress-induced release of ACTH and corticosterone was reduced, leading to more exploratory behavior and less anxiety.
20. 1 displayed less anxious behaviour and did not have a normal response to stress.
21. Penalva RG, Flachskamm C, Zimmermann S, Wurst W, Holsboer F, Reul JMHM, Linthorst ACE: Corticotropin-releasing hormone receptor type 1-deficiency enhances hippocampal serotonergic neurotransmission: An in vivo microdialysis study in mutant mice. Neuroscience (2002) 109(2):253-266.
22. 1 receptors. Science (2002) 296(5569):931-933.
23. Müller MB, Keck ME: Genetically engineered mice for studies of stress-related clinical conditions. J Psychiatr Res (2002) 36(2):53-76.
24. 1 receptors in amygdala. J Neurosci (2002) 22(7):2926-2935.
25. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Coman M, Dunaiskis A, Faraci S, Schmidt AW, Seeger T, Seymour P et al: CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA (1996) 93(19):10477-10482.
26. 1 receptor antagonist. Eur J Pharmacol (1997) 323(1):21-26.
27. Hikichi T, Akiyoshi J, Yamamoto Y, Tsutsumi T, Isogawa K, Nagayama H: Suppression of conditioned fear by administration of CRF receptor antagonist CP-154,526. Pharmacopsychiatry (2002) 33(5):189-193.
28. Wong M-L, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE, Geracioti TD Jr, DeBellis MD , Rice KC et al: Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci USA (2000) 97(1):325-330.
29. 1 antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent. Neuropsychopharmacology (2001) 25(4):585-600.
30. 1 receptor antagonists, CRA1000 and CRA1001. Eur J Pharmacol (1999) 371(2-3):205-211.
31. Otagiri A, Wakabayashi I, Shibasaki T: Selective corticotropin-releasing factor type 1 receptor antagonist blocks conditioned fear-induced release of noradrenaline in the hypothalamic paraventricular nucleus of rats. J Neuroendocrinol (2000) 12(10):1022-1026.
32. Liebsch G, Linthorst ACE, Neumann I, Reul JMHM, Holsboer F, Landgraf R: Behavioral, physiological, and neuroendocrine stress responses and differenial sensitivity to diazepam in two wistar rat lines selectively bred for high- and low-anxiety-related behavior. Neuropsychopharmacology (1998) 19(5):381-396.
33. 1 receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci (2001) 13(2):373-380. Increasing doses of R-121919 decreased anxiety-like behavior in rats with high innate anxiety.
34. 1 receptor antagonist R121919 attenuates stress-elicited sleep disturbances in rats, particularly in those with high innate anxiety. J Psychiatr Res (2002) 36(4):197-208.
35. 1-receptor-antagonist R121919 improves sleep-EEG in patients with depression. J Psychiatr Res (2003): in press.
36. 1 antagonist that demonstrated potentially promising results.
37. 1 antagonist R121919/NBI 30775 in patients with depression. J Psychiatr Res (2003): in press.
38. 1 receptors and had anxiolytic effects in different animal models of anxiety.
39. Grigoriadis DE, Chen C, Wilcoxen K, Chen T, Lorang MT, Bozigion H, Lia X-J, Ling N, McCarthy JR, De Souza EB, Vale WW: In vitro characterization of R121919: A novel non-peptide corticotropin-releasing factor 1 (CRF1) receptor antagonist for the potential treatment of depression and anxiety-related disorders. Abstr Soc Neurosci (2000) 26: Abs 807.4.